Company Overview

ADC Therapeutics SA is a clinical-stage biotechnology company focused on the development and commercialization of antibody-drug conjugates (ADCs) for the treatment of hematologic malignancies and solid tumors. The company operates within the oncology biopharmaceutical industry and develops targeted therapies designed to deliver cytotoxic payloads directly to cancer cells while limiting systemic exposure. Its lead commercial product is ZYNLONTA (loncastuximab tesirine-lpyl), an ADC approved in the United States for certain patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company’s broader pipeline includes ADC candidates targeting both blood cancers and solid tumors through proprietary linker and payload technologies.

ADC Therapeutics was founded in 2011 and is headquartered in Lausanne, Switzerland. The company evolved from an early-stage oncology research organization into a publicly traded biotechnology company listed on the New York Stock Exchange under the ticker ADCT. Its strategic positioning is based on specialized expertise in pyrrolobenzodiazepine (PBD)-based ADC technology, targeted oncology drug development, and partnerships with larger pharmaceutical and biotechnology firms. Revenue generation has historically been driven primarily by product sales of ZYNLONTA, licensing arrangements, and collaboration-related payments tied to development partnerships and research agreements.

Business Operations

ADC Therapeutics organizes its operations around the development, regulatory advancement, and commercialization of ADC therapies. Its primary operating focus includes the commercialization of ZYNLONTA and advancement of its clinical-stage oncology pipeline. The company generates revenue through product sales, milestone payments, licensing agreements, and collaborative research arrangements. Commercial activities are concentrated primarily in the United States, while research, clinical development, and corporate functions support broader international operations. The company has also relied on contract manufacturing organizations and external research partners to support development and production activities.

The company controls proprietary ADC technologies, including linker systems and PBD dimer payload platforms used in targeted cancer therapies. ADC Therapeutics has entered into strategic collaborations with biotechnology and pharmaceutical companies, including licensing and co-development arrangements related to ADC platforms and oncology targets. Subsidiaries and operational entities support activities in Switzerland, the United States, and the United Kingdom. Public filings and investor disclosures identify relationships with manufacturing partners, clinical research organizations, and commercial service providers as important operational components supporting regulatory and commercialization efforts.

Strategic Position & Investments

ADC Therapeutics’ strategic direction centers on expanding its oncology portfolio through clinical development of next-generation ADC therapies and maximizing the commercial potential of ZYNLONTA. Growth initiatives include pursuing additional indications for approved therapies, advancing combination treatment studies, and developing novel ADC candidates targeting both hematologic and solid tumor markets. The company has emphasized investment in differentiated ADC technologies intended to improve therapeutic efficacy and target selectivity in oncology treatment.

The company has made substantial investments in clinical-stage pipeline programs and intellectual property related to ADC payload and linker technologies. Strategic priorities disclosed in public filings and investor materials include operational efficiency, clinical trial advancement, and selective partnering opportunities. ADC Therapeutics has also explored external collaborations to broaden development capabilities and expand geographic reach. While the company maintains a focused oncology portfolio rather than a diversified conglomerate structure, its research activities position it within emerging targeted cancer therapy sectors, including precision oncology and advanced biologic therapeutics.

Geographic Footprint

ADC Therapeutics maintains a multinational operational footprint anchored by its headquarters in Lausanne, Switzerland, with significant commercial and operational activities in the United States. The company’s U.S. presence supports commercialization, regulatory affairs, medical affairs, and clinical development related to ZYNLONTA and pipeline candidates. Additional operational functions and partnerships extend into the United Kingdom and other parts of Europe through research collaborations, manufacturing relationships, and clinical trial activities.

The company’s clinical development programs have involved trial sites and regulatory interactions across North America, Europe, and selected international markets. Commercial exposure remains most significant in the U.S. oncology market due to FDA approval of ZYNLONTA, though the company continues to evaluate broader international opportunities through partnerships and regulatory engagement. Its global operational influence is primarily concentrated in oncology drug development, supply chain coordination, and cross-border clinical research activities.

Leadership & Governance

ADC Therapeutics is led by an executive management team with backgrounds in oncology drug development, biotechnology commercialization, and pharmaceutical operations. The company’s governance structure follows public-company standards applicable to NYSE-listed issuers and Swiss corporate requirements. Leadership strategy has emphasized disciplined oncology portfolio development, advancement of ADC technologies, and commercialization of targeted cancer therapies through focused capital allocation and clinical execution.

Key executives identified in recent public filings and company disclosures include:

• Ameet Mallik – Chief Executive Officer
• Samir Hirawat, M.D. – President and Head of Research & Development
• Jay Feingold, M.D., Ph.D. – Senior Vice President and Chief Medical Officer
• Ameet Nathwani, M.D. – Chairman of the Board of Directors
• Paula Soteropoulos – Member of the Board of Directors
• Peter B. Corr, Ph.D. – Member of the Board of Directors

Leadership communications in investor presentations and corporate filings consistently emphasize innovation in ADC therapeutics, disciplined clinical development, and long-term value creation through targeted oncology specialization. Information regarding executive roles and governance structure has been corroborated through SEC filings, company annual reports, and public investor materials.